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FusionAlterations in mitochondrial function may have a central role in the pathogenesis of many neurodegen-
erative diseases. The study of mitochondrial dysfunction has typically focused on ATP generation, calcium
homeostasis and the production of reactive oxygen species. However, there is a growing appreciation of the
dynamic nature of mitochondria within cells. Mitochondria are highly motile organelles, and also constantly
undergo ﬁssion and fusion. This raises the possibility that impairment of mitochondrial dynamics could
contribute to the pathogenesis of neuronal injury. In this review we describe the mechanisms that govern
mitochondrial movement, ﬁssion and fusion. The key proteins that are involved in mitochondrial ﬁssion and
fusion have also been linked to some inherited neurological diseases, including autosomal dominant optic
atrophy and Charcot–Marie–Tooth disease 2A. We will discuss the evidence that altered movement, ﬁssion
and fusion are associated with impaired neuronal viability. There is a growing collection of literature that
links impaired mitochondrial dynamics to a number of disease models. Additionally, the concept that the
failure to deliver a functional mitochondrion to the appropriate site within a neuron could contribute to
neuronal dysfunction provides an attractive framework for understanding the mechanisms underlying
neurologic disease. However, it remains difﬁcult to clearly establish that altered mitochondrial dynamics
clearly represent a cause of neuronal dysfunction.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria play a vital role in the maintenance of the viability of
neurons. Clearly established functions include oxidative phosphory-
lation to supply ATP, as well as a critical role in calcium homeostasis
[1]. It is widely appreciated that the interruption of mitochondrial
function in neurons is typically associated with the initiation or
ampliﬁcation of neuronal injury [2–4]. Perhaps the most acute and
dramatic example of mitochondrial failure would be in cerebral
ischemia where the loss of oxygen and glucose, the key mitochondrial
substrates, results in a rapid onset and severe injury to neurons.
However, there are many other pathophysiological states that may be
substantially inﬂuenced by mitochondrial dysfunction that are more
subtle than acute bioenergetic collapse, and these injury mechanisms
may be manifested more slowly, in distinct compartments within
neurons, or potentially even within a subset of mitochondria inside a
single neuron.
From a cell biological standpoint, mitochondria within neurons are
also very dynamic. It has been appreciated for many years that
mitochondria may move rapidly and over relatively long distances in
neurons (reviewed in [5]). More recently, it has become clear that
mitochondria can undergo ﬁssion and fusion [6–8]. Moreover,
changing the overall balance of ﬁssion and fusion can alter the sizelds).
ll rights reserved.of discrete mitochondria from relatively short bodies to electrically
contiguous, highly branched organelles that can stretch for hundreds
of microns across a single cell [9]. Indeed, given the plasticity in the
ﬁssion and fusion process a consideration of the number of
mitochondria within a cell becomes meaningless, while the overall
mitochondrial mass is a more relevant, if harder to measure,
parameter.
While mitochondrial dynamics in neurons are clear and easy to
observe, the purpose of mitochondrial movement (or trafﬁcking) or
alterations in mitochondrial morphology is less obvious. One can
readily develop a scheme that envisages the generation of new
mitochondria in the proximity of the neuronal nucleus, themovement
of mitochondria to sites of high ATP demand or calcium inﬂux, the
functioning of mitochondria at those sites for a ﬁnite period of time
and then the trafﬁcking of old and dysfunctional mitochondria to a
subcellular graveyard for their autophagic demise [10]. These schemes
are based on observations that essentially represent snapshots of
mitochondrial function over relatively short periods of time (minutes
to hours) in relation to the actual lifetime of a single organelle. While
attractive and conceptually satisfying, this view of mitochondrial life
cycle lacks rigorous experimental demonstration. It is very difﬁcult to
establish where new mitochondria are made in neurons (but see
[11]), and there are no data that demonstrate an orderly progression
of mitochondria from a site of biogenesis into the neuropil. While
autophagy is a likely mechanism for mitochondrial disposal, the
extent to which autophagy contributes to the overall turnover of
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half life of brain mitochondria was estimated to be N15 days in studies
performed nearly 50 years ago [12] remarkably little is known about
the characteristics of mitochondrial turnover in neurons.
Nevertheless, even in the absence of a solid understanding of the
physiological characteristics of mitochondrial dynamics, it is becom-
ing clear that pathophysiologic events can profoundly impact
mitochondrial trafﬁcking and morphology. A variety of neurotoxic
stimuli can halt mitochondrial movement, and separately there are
factors that appear to trigger mitochondrial fragmentation that are
also associated with neuronal injury. From the kinds of observations
that will be reviewed here, it can be hypothesized that interrupting
normal mitochondrial dynamics causes neuronal injury.
In this review we will critically evaluate this hypothesis. We will
review the physiological mechanisms and characteristics of both
mitochondrial trafﬁcking and mitochondrial morphology, and then
describe the evidence showing that these processes are altered by
neurotoxic stimuli. In some, but not all, cases there are established
mechanisms that can account for the alterations in mitochondrial
dynamics. A more challenging issue is the determination of whether
altered mitochondrial dynamics actually drive neuropathology, or
whether these changes are injury-related epiphenomena, and this
will also be a focus of the review.
2. Mitochondrial trafﬁcking in neurons
2.1. Mechanism and purposes of mitochondrial trafﬁcking
2.1.1. Trafﬁcking machinery
There have been several excellent and recent reviews that provide
detailed descriptions of the current understanding of the cellular
machinery that is responsible for moving mitochondria within a
variety of cell types including neurons [5,13–15]. The brief summary
of these mechanisms that follows is based on these reviews.
Mitochondria in neuronal processes undergo saltatory anterograde
and retrograde movement while retaining their identity as discrete
organelles. Individual organelles are readily observed to start, stop,
move over distances of tens or hundreds of microns at a velocity of
several microns per second and to change direction of movement.
From the observation of mitochondrial movement in dendrites and
axons in cultured neurons it is inferred that mitochondria could be
undergoing purposeful movement from one destination in the cell to
another, although practical limitations of imaging preclude tracking
an individual organelle over more than a relatively modest distance,
so the true origin and destination of any givenmitochondrion remains
an inference. The primary mechanism for long-distance movement of
mitochondria requires microtubules. It is clear that anterograde
axonal movement of mitochondria is generated by plus end-directed
kinesins. Of the large number of kinesin family members, kinesin-1
and kinesin-3 appear to contribute to the movement of mitochondria.
Retrograde axonal movement is likely to be mediated by dyneins.
There are far fewer dynein heavy chains in vertebrates compared to
the extensive family of kinesins, and cargo speciﬁcity is likely
provided by a range of accessory proteins. Mitochondria can also
move along the actin cytoskeleton. Several forms of myosin are found
in neuronal processes, andmyosin Vmay be themost likely form to be
involved in mitochondrial attachment and movement along actin
ﬁbers.
2.1.2. Docking and regulation of mitochondrial movement
Mitochondria alternate between saltatory movement and being
stationary, and this is presumably a regulated process. The physio-
logical control of this mitochondrial movement can, in principle, be
accomplished in several ways. This includes the regulation of the
attachment of mitochondria to the main motor proteins, and also
includes docking or anchoring of mitochondria to static sites such asactin as well as other as yet unidentiﬁed cellular entities. Milton was
recently identiﬁed as a motor adaptor protein that links kinesin
motors to mitochondria in Drosophila axons to enable anterograde
movement [16]. While synapses form normally in Milton null ﬂies
they lack mitochondria in axons and presynaptic terminals. Miro is an
outer mitochondrial membrane protein that is found in complexes
with Milton. Deletion of Miro in Drosophila also prevents mitochon-
drial delivery to synapses and diminishes neuromuscular transmis-
sion [17]. A number of studies have demonstrated that increases in
intracellular calcium regulate mitochondrial trafﬁcking (see below).
Interestingly, Miro contains an E–F hand domain, and several studies
have demonstrated that the calcium-sensitive regulation of mito-
chondrial movement, whereby calcium diminishes movement,
requires the presence of Miro [18–21]. Another kinesin-associated
protein that enables anterogrademitochondrial movement in axons is
syntabulin [22]. It is perhaps to be anticipated that the collection of
adaptor proteins that inﬂuence the anterograde and the retrograde
movement of mitochondria will continue to grow, and with this
growth will emerge a more complete appreciation of potential
regulatory signals that control movement.
2.1.3. Distribution of mitochondria in neurons
Until relatively recently, many of the detailed studies of mito-
chondrial distribution in neurons were essentially static evaluations
performed on ﬁxed tissues. These studies established that mitochon-
dria are typically located at sites of high ATP demand, including
synapses, growth cones, nodes of Ranvier and myelination/demye-
lination interfaces (reviewed in [5,10]). It is also clear that alterations
in activity change the overall density of mitochondria, determined
using cytochrome oxidase staining [23]. The use of ﬂuorescence
imaging approaches in cultured cells has allowed the real-time
assessment of more dynamic aspects of mitochondrial distribution in
live neurons. These studies have established the general character-
istics of mitochondrial movement in both axons and dendrites of
central and peripheral neurons [24–29]. These studies consistently
demonstrate bidirectional movement of mitochondria, a subset of
motilemitochondria while themajority remain stationary, and a ﬁnite
frequency of apparent ﬁssion and fusion events (discussed in more
detail below). There is relatively little information available about the
interaction of individual mitochondria with speciﬁc locations within
neurons. However, the potential for local signalling regulating
trafﬁcking was elegantly illustrated by Chada and Hollenbeck [30]
who demonstrated that mobile mitochondria responded to the local
application of nerve growth factor to an axon by becomingmore likely
to stop. Mitochondria also respond to synaptic stimulation, where an
increase in synaptic activity increases the probability that mitochon-
dria will stop at a post-synaptic site [31–33]. Conversely, inhibiting
synaptic activity with tetrodotoxin results in an overall increase in
mitochondrial motility, perhaps reﬂecting a reduction in calcium
mediated docking [31–33].
These studies clearly support the concept that some or all
mitochondria are mobile within neurons, and that on a local basis
and in response to acute stimulation, mitochondria can stop moving
and dock at locations that are probably associated with an increased
demand for ATP. It is harder to establish the nature of “long-distance”
signals within neurons that direct the trafﬁcking of mitochondria to
speciﬁc, distant locations. Indeed, one can question whether such
signals are even required. It is also important to recognize in the
context of neurons that essentially all of the trafﬁcking studies focus
on mitochondria that are in the axons and/or dendrites of neurons.
Formally, it is not clear whether the behavior of mitochondria in
neuronal cell bodies is the same as that in processes or, indeed,
whether somatic mitochondria are in equilibrium with those in
processes. It is interesting to consider the concept of networked
mitochondria in the context of neurons. There are a number of
interesting illustrations of complex, reticulated mitochondria that are
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been reported in neuron dendrites, but not axons, using serial
reconstructions from electron micrographs [35]. However, the studies
cited above that track moving mitochondria do not report the
presence of large reticulated mitochondria in either axons or
dendrites of neurons in cultures (although the presence of such
structures in cell bodies would go undetected). Alterations in the
activity of ﬁssion or fusion proteins clearly has an impact on
trafﬁcking [31,36], but the nature of the interplay between the
formation of mitochondrial networks and the dynamic distribution of
mitochondria within neurons remains unclear.
2.2. Impairment of trafﬁcking in neuronal injury
It is widely believed that impairment of the bioenergetic function
of mitochondria contributes to neuronal injury. The developing thesis
in this review is that the location of the mitochondrion in the neuron
has an important inﬂuence on the ability of the organelle to meet the
bioenergetic demands of the cell. A combination of these two concepts
suggests that factors that impact the mobility of mitochondria could
impair neuronal viability. In fact, accumulating literature suggests that
there is an association between the action of some neurotoxins and
the impairment of mitochondrial movement, although this impair-
ment results from several quite distinct mechanisms. In this section
we will review the neurotoxic mechanisms that inhibit trafﬁcking,
and then pose the question of whether impaired movement has been
established to be causative of neuronal injury.
2.2.1. Bioenergetic failure
Glutamate is a well-studied neurotoxin in primary neurons. Acute
application of high concentrations of glutamate activates calcium
entry through N-methyl-D-aspartate (NMDA) receptors, and this
ultimately results in a delayed neuronal death that occurs 24–48
h later. It is clear that the large amounts of calcium that enter neurons
through NMDA receptors must be taken up into mitochondria for
injury to be expressed [37–39]. Additionally, this acute calcium load
results in profound mitochondrial depolarization, which presumably
limits ATP production [40,41]. Using neurons that expressed a
mitochondrially targeted yellow ﬂuorescent protein, we found that
NMDA receptor activation resulted in a rapid cessation of mitochon-
drial movement and also a decrease in mean mitochondrial length
[42], effects that were spatially limited to dendrites, rather than axons,
where NMDA receptors are located [32]. The role of calcium will be
discussed further below, but a series of experiments designed to
manipulate the bioenergetic state of mitochondria independently of
changes in intracellular calcium suggested that ATP production was
key to support trafﬁcking. Thus, depolarizing mitochondria with the
uncoupler FCCP, as well as inhibiting ATP synthesis with oligomycin
both effectively impair movement [42,43]. Interestingly, another
electron transport chain inhibitor, nitric oxide, inhibits mitochondrial
movement at similar concentrations to those that dissipate mito-
chondrial membrane potential [44,45]. Collectively, these ﬁndings
support the idea that mitochondrial ATP generation must be intact in
order to support mitochondrial trafﬁcking, perhaps because locally
produced ATP serves as the fuel that drives the cellular motors that
move mitochondria.
2.2.2. Ionic signals—calcium and zinc
The action of calcium following excitotoxic stimulation could be
the result of several different phenomena. As described here, NMDA-
mediated calcium overload certainly causes a bioenergetic impair-
ment. However, a number of studies have suggested that calcium
regulates mitochondrial movement separately from a mechanism
involving bioenergetic failure. For example, in cardiac myocytes,
elevating cytosolic calcium to 1–2 μM results in the complete arrest of
mitochondrial movement along microtubules [46]. It is tempting tosuggest that this mechanism is mediated by calcium binding to Miro,
as is observed in Drosophila neurons as described above [18,20,21,47].
However, it is also clear that not all calcium signals impact
mitochondrial movement. While glutamate and calcium ionophores
arrest movement [20,42], stimuli that produce robust but smaller
calcium changes, such as kainate or depolarization with potassium, do
not [42,48]. This contrasts with the suggestion that normal physio-
logical calcium changes broadly regulate motility in neurons in
culture [18,20,21,47].
Zinc is an important trace metal that has been implicated in a
number of neurodegenerative disease states [49]. Zinc can substitute
for calcium in many transport processes and is transported and
putatively released bymitochondria [50]. Elevated intracellular zinc is
toxic to neurons in primary culture at relatively low concentrations.
Studies that illustrated the minimally effective toxic exposure to
intracellular zinc also showed that zinc blocked mitochondrial
movement in primary neurons [51]. This effect was independent of
any clear impact on the bioenergetic function of neurons. Interest-
ingly, the effect of zinc on mitochondrial movement and on
neurotoxicity was blocked by wortmannin, which affords a transient
inhibition of PI-3 kinase activity at the concentrations used in this
study [51]. These ﬁndings provide a parallel to the conclusions of
Chada and Hollenbeck [30] who reported that NGF promoted
mitochondrial docking which may also be associated with PI-3 kinase
activation. It should also be noted that zinc clearly produces other
effects on mitochondria at slightly higher concentrations than those
that activate PI-3 kinase. These effects include mitochondrial
depolarization, and are associated with a form of injury that is not
blocked by wortmannin [51].
2.2.3. Disease-causing proteins and mitochondrial trafﬁcking
There is a growing body of evidence that proteins associated with
neurodegenerative disease can impact axonal transport of organelles
in general and mitochondria in particular. A conceptually simple
mechanism by which this might occur is through the formation of
aggregates in neuronal processes that block transport. One example of
this is provided by neurons expressing expanded polyglutamine
forms of huntingtin, the protein responsible for Huntington's disease.
In these neurons aggregates were invariably associated with mito-
chondria, and regions of the neurite around the aggregate displayed
less mitochondrial movement [52]. There are a number of reports that
describe other interactions with mitochondrial trafﬁcking, including
decreased mitochondrial velocity [53], and an impairment of the
association of mitochondria with microtubule-based transport pro-
teins [54]. It is not clear that the impairment of trafﬁcking is speciﬁc to
mitochondria in mtHtt expressing cells, as vesicular trafﬁcking is also
impacted [55,56]. However, the effect of slowing mitochondrial
delivery to sites of ATP demand distal to an aggregate-blocked
process provides a conceptually appealing mechanism to account for
the slowly developing loss of striatal neuron function that is
associated with this disease.
Unlike Huntington's disease, amyotrophic lateral sclerosis is
largely a sporadic disease. However, the disease has been effectively
modeled in mice by the overexpression of mutant forms of copper-
zinc superoxide dismutase (mtSOD1), which was identiﬁed in the less
common familial forms of the disease. In neurons derived from
mtSOD1 expressing mice, profound mitochondrial defects are
observed to coincide with the appearance of motor neuron pathology
[57]. In addition, there is evidence for decreased entry of mitochon-
dria into axons beyond the initial segment as well as decreased
retrograde transport of mitochondria in the axons of motor neurons
[58,59] from studies of mtSOD1 mice. More recently, direct observa-
tion of mitochondrial trafﬁcking in motor neurons has shown that
trafﬁcking is impaired by mtSOD1 [60,61]. The mechanism of
impaired transport is not entirely clear. Mutant SOD1 is found
associated with mitochondria, and it is possible that this disrupts the
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Like mtHtt, mtSOD1 also aggregates, allowing for the possibility of a
physical obstruction. However, it is also clear that metabolic
dysfunction could be a key early event, so that disrupting the delivery
of ATP to the motors would be involved in the cessation of movement
[61].
The microtubule associated protein tau when hyperphosphory-
lated forms neuroﬁbrillary tangles that are one of the hallmarks of
Alzheimer's disease [62]. Tau can also have an important impact on
mitochondrial trafﬁcking. Tau interferes with the attachment of
cargoes to kinesin-based motors, so that tau overexpression results in
the accumulation of mitochondria near theminus end of microtubules
in the center of the cell [63]. In primary neurons, tau overexpression
results in the depletion of mitochondria from neurites [64].
Phosphorylation of tau results in its dissociation from microtubules
and their subsequent destabilization [65] which would interrupt the
delivery of mitochondria to key cellular sites. Both amyloid precursor
protein (APP) and apolipoprotein E4 can interact with mitochondria
and impair bioenergetic function [66,67](reviewed in [4]), and these
could result in the impairment of mitochondrial trafﬁcking. It remains
a challenge to attribute the key pathology in Alzheimer's disease to a
single pathogenic mechanism, but impairing the delivery of mito-
chondria to presynaptic sites in axons and the subsequent loss of
synaptic activity again provides an appealing mechanism to account
for a disease characterized by the progressive loss of synaptic
connections.
2.3. Mitochondrial trafﬁcking defects in neurodegeneration: cause or
effect?
This section has identiﬁed associations between a number of
mechanisms associated with neurodegeneration where there is also
evidence for impairment of mitochondrial trafﬁcking. Both acute and
chronic neurodegenerative disease states may feature trafﬁcking
disruptions, and it seems self evident that if mitochondria are not
delivered to the right place at the right time the viability of the neuron
will be negatively affected. On the other hand, it is clear that some of
the mechanisms that impact trafﬁcking could very readily be
secondary to the main pathogenic event. For example, if the primary
pathogenic event involves bioenergetic disruption, then it is very
likely that mitochondria will ultimately stop moving. However, it
would be difﬁcult to conclude that the cessation of trafﬁcking was the
cause of the neuronal injury. Many of the examples cited here, such as
glutamate excitotoxicity, mtHtt, mtSOD1 and ApoE4 mediated injury,
have also been associated with bioenergetic dysfunction, so it remains
to be established exactly how the alteration in trafﬁcking contributes
to the injury process. Indeed, at this point it is difﬁcult to
unequivocally attribute any neurodegenerative disease state to
impaired delivery of mitochondria as a primary cause. With a greater
appreciation of the speciﬁc mechanisms that transport mitochondria
in neurons it may be possible to design an approach that interrupts
mitochondrial trafﬁcking selectively, while leaving other transport
processes intact, to determine whether the trafﬁcking defect is
actually toxic. Even then, toxicity may still only be evident when
the trafﬁcking defect is coupled with the imposition of a cellular
stressor, which additionally challenges the design of the deﬁnitive
experiment.
3. Mitochondrial morphology and neuronal injury
In addition to the dynamic movement of mitochondria within
neurons, it is also clear that mitochondria can change shape. The
typical morphology of a mitochondrion observed in an axon or
dendrite is a ﬁlamentous structure that ranges from a few microns to
several tens of microns long. As described in this section, it has
become clear that the morphology and interconnectedness ofmitochondria is dynamically controlled by a series of proteins, and
also that mitochondria routinely undergo ﬁssion and fusion for
purposes that are not yet entirely clear [6,7]. In addition, there is an
emerging view that morphology of mitochondria may change in
associationwith injury. In this section wewill review themechanisms
controlling mitochondrial morphology, and then critically evaluate
the proposal that altered morphology drives neuronal viability.
3.1. Regulating mitochondrial morphology in neurons
3.1.1. Fission proteins
The dynamin-related protein 1 (Drp1) gene from Caenorhabditis
elegans [68] was one of the ﬁrst genes shown to be involved in
mediating mitochondrial ﬁssion. Overexpression of Drp1 results in
fragmented mitochondria in C. elegans [68] and in mammalian
neurons [69]. Smirnova and her colleagues reported that transfection
of COS-7 cells with a dominant-negative Drp1 results in more
interconnected mitochondria [70], and that Drp1 is localized to
mitochondrial scission points [71], further supporting the assertion
that Drp1mediatesmitochondrial ﬁssion. These effects have also been
observed in cortical neurons; Uo and colleagues [72] reported that
shRNA-mediated reduction of endogenous Drp1 or expression of a
dominant-negative Drp1 results in elongated mitochondria.
Recently, a mechanism of regulation of Drp1-mediated ﬁssion has
been reported which links high calcium levels associated with
excitotoxicity and mitochondrial ﬁssion. Elevated calcium may
activate calcineurin which in turn dephosphorylates Drp1. Drp1 is
then translocated to mitochondria where it induces ﬁssion [73–75].
The dynein/dynactin complex [76] and actin [77] have also been
reported to play a role in regulating translocation of Drp1 to
mitochondria, although the role of these elements has yet to be
investigated in neurons. The activity of Drp1 has also been reported to
be modulated by sumoylation [78,79] and mitochondrial membrane
potential [77].
3.1.2. Fusion proteins
The ﬁrst protein involved in mitochondrial fusion was identiﬁed
by Hales and Fuller [80] in the Drosophila “fuzzy onions” mutant.
During Drosophila spermatogenesis, this protein (fzo) was shown to
mediate the fusion of mitochondria. Two human homologues,
Mitofusin 1 (Mfn1) and Mitofusin 2 (Mfn2), were subsequently
identiﬁed [81]. Overexpression of Mfn2 in COS-7 cells caused
normally punctate mitochondria to become more elongated, an effect
that was more pronounced when cells were co-transfected with a
dominant-negative form of Drp1 (Drp1-K38A) [81]. These results
suggest that mitochondrial morphology is the result of a balance
between the opposing effects of Drp1 and the mitofusins. More
recently, it has been shown that Mfn1 and Mfn2 may act together in a
heterooligomeric complex to control fusion [82].
Another highly studied gene proposed to play a role in mitochon-
drial dynamics is optic atrophy protein 1 (OPA1). Loss of OPA1 has
been associated with compromise of the inner mitochondrial
membrane, cytochrome C release and subsequent apoptosis [83].
The OPA1 gene has eight alternative splice variants [84] and complex
posttranslational processing including proteolytic cleavage [85,86].
Interestingly, the activity of OPA1 may be modulated by this cleavage,
a process that has been linked to the bioenergetic state of the cell;
dissipation of the mitochondrial membrane potential, the driving
force for ATP production, has been reported to induce proteolytic
processing of OPA1 and subsequent mitochondrial fragmentation
[86–88]. Moreover, altered OPA1 processing has been linked to ATP
depletion [89].
In mammalian cells the fusion-inducing proteins described above
are required, and operate in concert to fuse two mitochondria. In a
recent paper Song et al [90] describe how the mitofusins (Mfn1 and
Mfn2) and OPA1 mediate separate sequential mitochondrial mem-
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membrane fusion whereas OPA1 is required for inner membrane
fusion.
3.2. Mitochondrial morphology and neuronal injury
3.2.1. Diseases associated with mitochondrial ﬁssion/fusion disruption
The importance of proper maintenance of mitochondrial mor-
phology in neurons is underscored by the disease states associated
with mutations in mitochondrial morphology inﬂuencing proteins. As
illustrated by the examples below, mutations in morphology-
controlling genes result in both spatial and temporally speciﬁc
neurodegeneration.
Mutations in OPA1 are associated with autosomal dominant optic
atrophy, a progressive degenerative disease of the optic nerve
[91,92]. The disease has a juvenile onset and manifests itself through
a selective degeneration of retinal ganglion cells. The result is a
progressive loss of visual acuity, and eventually blindness. It remains
an open question as to why retinal ganglion cells are selectively
vulnerable to a disease associated with a mitochondrial fusion
defect.
Mutations in Mfn2 have been implicated in Charcot–Marie–Tooth
disease 2A (CMT2A) [93]. CMT2A is a peripheral neuropathy which
targets the axons of sensory and motor neurons. Degeneration of
these peripheral neurons results in muscle weakness, primarily in the
lower limbs [94]. In addition to deﬁcits in mitochondrial fusion,
impairment of mitochondrial transport has also been reported as a
consequence of expression of mutant Mfn2 [95]. This may in part
explain why long peripheral nerves are targeted in this disease [95].
Recently Parkinson's and Alzheimer's diseases have also been
associated with changes in mitochondrial morphology, although in
contrast to the above disorders, they are usually associated with
advanced age. Loss of function mutations or deletions of the
Parkinson's associated genes PTEN-induced kinase 1 (Pink1) and
parkin have been shown to be associated with mitochondrial
fragmentation in several mammalian cell expression systems [96–99].
Studies in Drosophila have shown that loss of function mutations or
deletions of Pink1 and parkin impact upon mitochondrial dynamics
[100,101]. The studies in Drosophila are a little harder to interpret,
because they reﬂect Pink1/parkin modulation of mitochondrial
morphology driven by ﬁssion or fusion protein expression, but the
conclusion appears to be that the Parkinson's proteins promote
ﬁssion in the ﬂy. Observing opposite effects of Pink1 and parkin
depending on expression system begs the question of whether these
effects reﬂect a direct modulation of ﬁssion, or whether the effects
are secondary to an alteration in mitochondrial function [102].
Fibroblasts isolated from Alzheimer's patients exhibit signiﬁcantly
decreased Drp1 and exhibited elongated mitochondria, suggesting a
role for alterations in mitochondrial dynamics in the pathogenic
mechanism [103]. Additional studies also revealed evidence for
amyloid β-induced mitochondrial fragmentation in neuronal cells
and in Alzheimer's brain tissue [104,105]. The toxic effect of Aβ
oligomers on mitochondria is also correlated with alterations in spine
density and synaptic connectivity. As noted above, hyperphosphor-
ylation of tau can potentially disrupt mitochondrial trafﬁcking, but
based on current knowledge of Alzheimer's disease pathophysiology,
it could be argued that Aβ-mediated disruptions are upstream of
altered tau function.
There are several notable features that are shared by these
diseases. Firstly, even though the mutated proteins are found
throughout the body, the diseases are associated with relatively
speciﬁc neuronal pathologies, which suggest that there is some aspect
of neuronal physiology that is especially vulnerable to alterations in
ﬁssion and fusion. Secondly, it is notable that neurons can function
ostensibly normally for years or even decades before the effects of
these mutations become manifest. This suggests that the impact ofaltered ﬁssion and fusion is relatively subtle, and perhaps only results
in neuronal injury in the presence of an additional stressor, or as the
result of an accumulation of maladaptive events.
3.2.2. Acute morphological changes—ﬁssion, permeability transition or
rounding?
In our study examining the effects of excitotoxic glutamate on
mitochondrial motility and morphology in cortical neurons, we
observed a cessation of mitochondrial movement and signiﬁcant
reductions in mitochondrial length [42]. While the morphological
changes we observed resulted in an overall more fragmented
appearance of mitochondria, we observed that the majority of
mitochondria underwent a morphological change from being
thread-like to punctate, as measured by an increase in the “round-
ness” of individual mitochondria. Others have reported similar “rod-
like-to-rounded” morphology changes of mitochondria in neurons
[106,107] and astrocytes [108]. The mechanism underlying rounding
of mitochondria is not entirely clear. Under some circumstances
mitochondria lose the integrity of the inner membrane in a process
termed mitochondrial permeability transition. This is typically
characterized by swelling of isolated mitochondria, and could be
reﬂected by rounding of ﬁlamentous mitochondria in neurons [106]
[107]. It is also clear that there are substantial structural changes in
dendrites including beading [42] which could impact mitochondrial
shape.
In examining mitochondrial morphology changes we were
cautious in classifying what we observed as fragmentation, as
individual mitochondria could be clusters/chains of individual
mitochondria that pull apart. Similar microscopy limitations plague
quantiﬁcation of mitochondrial fusion, particularly in neurons where
mitochondria move along the restrictive pipelines of axons and
dendrites, passing above or below each other without fusing [109].
However, newly developed techniques employing photoactivatable
GFP targeted to mitochondria allows for quantitative assessment of
aggregate fusion rates [110] and direct visualization (and hence
quantiﬁcation) of both ﬁssion and fusion events [109].
3.3. What is the functional consequence of morphological change?
As described in the examples above, mutations in ﬁssion/fusion
genes can result in neurodegeneration. It has been suggested that the
unique energy requirements of neurons may in part explain why
diseases associated with these mitochondrial perturbations are
selective for neurons [111]. However, exactly how a deﬁcit in
fusion/ﬁssion causes neurodegeneration remains to be determined.
Therefore in this ﬁnal section we shall review the evidence linking
changes in morphology to mitochondrial function and injury.
3.3.1. Impact on mitochondrial physiology
In the study of mitochondrial dynamics, the impact of shifting
ﬁssion/fusion balance upon mitochondrial physiology remains rela-
tively unexplored; are smaller mitochondria functionally different
from larger mitochondria? i.e., Do longer/shorter mitochondria have
different membrane potentials, calcium sequestration ability, ATP
production or motility? It has been reported that disruption of
mitochondrial fusion in MEFs through knockout of Mfn1 and Mfn2 or
OPA1-RNAi results in loss of mitochondrial membrane potential in a
subset of mitochondria, and reduced respiration [112]. Conversely,
overexpression of Mfn2 in muscle cells has been shown to result in
mitochondrial fusion and an increase in mitochondrial metabolism
[113].
3.3.2. Impact on cellular viability
The link betweenmorphological changes induced by expression of
the mitochondrial-shaping genes described above and cell survival
was ﬁrst provided by Richard Youle and his colleagues [114]. They and
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undergo a transformation from reticular to punctuate morphology.
Youle and his colleagues also reported that following exposure to
apoptotic stimuli, overexpression of the dominant-negative Drp1
mutant (Drp1-K38A) results in maintenance of reticular mitochon-
dria, prevents loss of mitochondrial membrane potential, prevents
release of cytochrome c and blocks cell death [114]. This study
therefore provides evidence that mitochondrial ﬁssion may comprise
a step in apoptotic cell death. In addition, it has been subsequently
demonstrated in various cell types that fragmenting mitochondria
predisposes cells to injury [69], whereas fusing mitochondria can be
protective [116,117]. Interestingly, deleting Drp1 alters cytochrome c
release from mitochondria, but apparently does not impact frank
permeabilization of the mitochondrial outer membrane that is
associated with the release of apoptosis-triggering proteins [118],
again consistent with the idea that ﬁssion may be a modulator of
apoptotic cell injury.
While there is strong evidence that associates changes in
mitochondrial morphology with neuronal injury, and equally strong
evidence that altering mitochondrial morphology can predispose or
protect cells in injury paradigms, there is surprisingly little evidence
to support a causative role for (protein expression) induced
mitochondrial morphology changes in injury, i.e., fragmenting
mitochondria does not necessarily result in neuronal injury. It has
been reported that expression of Drp1 can result in neuronal cell
death [69]. However in this study, the authors report that a signiﬁcant
number of neurons displayed mitochondrial fragmentation but did
not die and conclude that mitochondria ﬁssion is a required element
in neuronal death but not sufﬁcient to cause injury on its own. In our
hands, overexpressing Drp1 in cortical neurons results in mitochon-
drial fragmentation, but does not have a signiﬁcant impact upon
neuronal health [119]. Others have also shown that inducing ﬁssion
through overexpression OPA1 has no signiﬁcant adverse effects on
cell viability, respiration rates or mitochondrial membrane potential
[112]. While fragmentation of mitochondria has been associated with
neuronal injury, there is little direct evidence of mitochondria
fragmentation initiating/causing injury. This argues that morpholog-
ical changes may comprise a step in injury mechanisms, but in some
cases the remodeling of mitochondria may in fact reﬂect a response
to injury.
4. Conclusions
It should be apparent that there is a rich and growing literature
that illustrates the interplay between mitochondrial dynamics,
morphology and neuronal function. Moreover, much of the emerging
information suggests that these alterations occur in the proximity of
neuronal injury. Based on observations made in several inherited
diseases, such as CMT2A, it is clear that there is a cause and effect
relationship between mutations in genes controlling mitochondrial
ﬁssion and fusion such that impaired fusion or excessive ﬁssion
decreases neuronal viability. It is tempting to extend this conclusion
to other disease states where altered mitochondrial morphology or
trafﬁcking is observed in response to neurotoxins, for example,
because the phenomena of altered morphology and impaired
trafﬁcking appear similar. However, unlike the rare genetic diseases,
the data at this time do not conclusively establish that the
mitochondrial changes represent a critical step in neuronal injury
rather than a closely-associated epiphenomenon.
There has been remarkable progress in the appreciation of the
mechanisms that are responsible for the movement of mitochondria,
the speciﬁcation of mitochondria as a cargo for cellular motors and
some of the factors that control movement and docking. Also, with the
development of imaging technologies, it has become possible to more
clearly study ﬁssion and fusion events in live cells. Collectively, these
studies reinforce the notion that mitochondria are highly dynamicorganelles. Given the unique architecture of neurons, the appearance
and potential impact of these dynamics is ampliﬁed. Mitochondria
move bidirectionally in neurons, and appear to dock speciﬁcally at
sites with increased ATP demands. They also appear to undergo a
frequent and on-going process of fusion and ﬁssion, the purpose of
which remains incompletely understood. However, these events are
readily observable in live cells and in real time.
It is also clear that mitochondrial dynamics are impacted by a
number of different cellular changes associated with disease states. As
noted above, mutations in ﬁssion and fusion protein genes are
associated with neurological diseases in humans, and this perhaps
provides the most direct evidence that alterations in ﬁssion or fusion
can cause disease. However, there are numerous additional examples
where pathogens stop mitochondrial movement (e.g., glutamate or
zinc), trap mitochondria around aggregated proteins (e.g., mtHtt) or
cause rounding or fragmentation of normally ﬁlamentous mitochon-
dria (e.g., calcium overload or Drp1 overexpression). In general, this
leads to the impression that circumstances in neurons associated with
immobile or fragmented mitochondria are associated with decreased
neuronal viability (although there are clearly exceptions to this view),
and it is tempting to propose that it is the dramatic changes in these
dynamics that cause pathology. This, however, remains hard to
convincingly establish with tools currently available, so that for most
of these phenomena we cannot establish whether immobilization of
mitochondria, for example, causes the death of the neuron, or
whether this is just a marker for the primary pathogenic event.
Additionally, while tracking ﬁssion, fusion or trafﬁcking events
acutely is highly feasible, it remains difﬁcult to monitor slower
changes in mitochondrial distribution or function that probably
would be a better representation of events that contribute to chronic
neurodegenerative disease. The evolution of molecular tools that
allow the inducible alteration of speciﬁc mitochondrial parameters
may represent the most fruitful way to address the question of cause
and effect.
There remain signiﬁcant gaps in understanding. There is very
limited information available to understand how mitochondrial
biogenesis contributes to the overall dynamics of mitochondria in
neurons, even though it is clear that mitochondrial expression is
closely tied to neuronal activity. It is also not clear how we should
view the overall turnover of mitochondria in neurons: are mitochon-
dria born, function for a ﬁnite time and are then cleared by autophagy,
or is it more appropriate to conceive of an organelle whose
components are constantly renewed and repaired by on-going protein
synthesis and DNA replication aided by the dilutive process of fusion
and ﬁssion? And ﬁnally, can we see these events in neurons in their
native environment in animals? The gaps in understanding are
signiﬁcant, but current knowledge suggests that this remains a fertile
area for further study.
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